Racial and ethnic differences in risk of second primary cancers among breast cancer survivors
- 383 Downloads
Disparities exist in breast cancer (BC) outcomes between racial and ethnic groups in the United States. Reasons for these disparities are multifactorial including differences in genetics, stage at presentation, access to care, and socioeconomic factors. Less is documented on racial/ethnic differences in subsequent risk of second primary cancers (SPC). The purpose of this study is to evaluate the risk of SPC among different racial/ethnic groups of women with BC. We conducted a retrospective cohort study of 134,868 Non-Hispanic White, 17,484 Black, 18,034 Hispanic, and 19,802 Asian/Pacific Islander (API) women with stages I–III BC in twelve Surveillance, Epidemiology and End Results Program registries between 2001 and 2010. Standardized incidence ratios (SIR), 95 % confidence intervals (CI), and absolute excess risks were calculated by comparing incidence of SPC in the cohort to incidence in the general population for specific cancer sites by race/ethnicity and stratified by index BC characteristics. All women were at increased risks of second primary BC and acute myeloid leukemia (AML), with higher risk among more advanced stage index BC. Black and API women had higher SIRs for AML [4.86 (95 % CI 3.05–7.36) and 5.00 (95 % CI 3.26–7.32)], respectively] which remained elevated among early-stage (I) BC cases. Women with a history of invasive BC have increased risk of SPC, most notable for second primary BC and AML. These risks for secondary cancers differ by race/ethnicity. Studies evaluating possible genetic and biobehavioral mechanisms underlying these differences are warranted. Strategies for BC adjuvant treatment and survivorship care may require further individualization with consideration given to race/ethnicity.
KeywordsBreast cancer Second primary cancer Racial/ethnic disparities Survivorship Surveillance
The authors would like to express their gratitude to Dr. Eric P. Winer for his guidance and comments on revisions of this manuscript.
Conflict of interest
The authors declare that they have no conflict of interest.
This work was supported by the National Institutes of Health (R25 CA094880) Cancer Prevention Training Grant in Nutrition, Exercise and Genetics at the University of Washington and the Carter Disparities Fund at Boston Medical Center. E.H.L. was supported by the 2014–2016 UIC/Takeda Fellowship in Health Economics and Outcomes Research.
- 2.American Cancer Society (2014) Cancer treatment and survivorship facts & figures 2014–2015. American Cancer Society Inc, AtlantaGoogle Scholar
- 4.American Cancer Society (2013) Breast cancer facts & figures 2013–2014. American Cancer Society Inc, AtlantaGoogle Scholar
- 9.Curtis E, Quale C, Haggstrom D, Smith-Bindman R (2008) Racial and ethnic differences in breast cancer survival: how much is explained by screening, tumor severity, biology, treatment, comorbidities, and demographics? Cancer 112(1):171–180. doi: 10.1002/cncr.23131 CrossRefPubMedCentralPubMedGoogle Scholar
- 10.Khatcheressian JL, Hurley P, Bantug E, Esserman LJ, Grunfeld E, Halberg F, Hantel A, Henry NL, Muss HB, Smith TJ, Vogel VG, Wolff AC, Somerfield MR, Davidson NE, American Society of Clinical O (2013) Breast cancer follow-up and management after primary treatment: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 31(7):961–965. doi: 10.1200/JCO.2012.45.9859 CrossRefPubMedGoogle Scholar
- 12.Ko NY, Darnell JS, Calhoun E, Freund KM, Wells KJ, Shapiro CL, Dudley DJ, Patierno SR, Fiscella K, Raich P, Battaglia TA (2014) Can patient navigation improve receipt of recommended breast cancer care? Evidence from the national patient navigation research program. J Clin Oncol 32(25):2758–2764. doi: 10.1200/JCO.2013.53.6037 CrossRefPubMedGoogle Scholar
- 13.Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Populations—Total U.S. (1969–2012) <Single Ages to 85+, Katrina/Rita Adjustment>—Linked To County Attributes—Total U.S., 1969–2012 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, Surveillance Systems Branch, released April 2014. Accessed September 2014
- 14.Singletary SE, Allred C, Ashley P, Bassett LW, Berry D, Bland KI, Borgen PI, Clark GM, Edge SB, Hayes DF, Hughes LL, Hutter RV, Morrow M, Page DL, Recht A, Theriault RL, Thor A, Weaver DL, Wieand HS, Greene FL (2003) Staging system for breast cancer: revisions for the 6th edition of the AJCC Cancer Staging Manual. Surg Clin N Am 83(4):803–819. doi: 10.1016/S0039-6109(03)00034-3 CrossRefPubMedGoogle Scholar
- 15.Surveillance Research Program, National Cancer Institute SEER*Stat software (seer.cancer.gov/seerstat) version < 8.1.5>Google Scholar
- 16.Balduzzi A, Castiglione-Gertsch M (2005) Leukemia risk after adjuvant treatment of early breast cancerGoogle Scholar
- 18.Le Deley M-C, Suzan F, Cutuli B, Delaloge S, Shamsaldin A, Linassier C, Clisant S, de Vathaire F, Fenaux P, Hill C (2007) Anthracyclines, mitoxantrone, radiotherapy, and granulocyte colony-stimulating factor: risk factors for leukemia and myelodysplastic syndrome after breast cancer. J Clin Oncol 25(3):292–300CrossRefPubMedGoogle Scholar
- 23.Smith RE, Bryant J, DeCillis A, Anderson S (2003) Acute myeloid leukemia and myelodysplastic syndrome after doxorubicin-cyclophosphamide adjuvant therapy for operable breast cancer: the National Surgical Adjuvant Breast and Bowel Project Experience. J Clin Oncol 21(7):1195–1204CrossRefPubMedGoogle Scholar
- 30.Pulte D, Redaniel MT, Jansen L, Brenner H, Jeffreys M (2013) Recent trends in survival of adult patients with acute leukemia: overall improvements, but persistent and partly increasing disparity in survival of patients from minority groups. Haematologica 98(2):222–229CrossRefPubMedCentralPubMedGoogle Scholar
- 32.Hershman D, Neugut AI, Jacobson JS, Wang J, Tsai W-Y, McBride R, Bennett CL, Grann VR (2007) Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy. J Natl Cancer Inst 99(3):196–205CrossRefPubMedGoogle Scholar
- 36.Stark A, Stapp R, Raghunathan A, Yan X, Kirchner HL, Griggs J, Newman L, Chitale D, Dick A (2012) Disease-free probability after the first primary ductal carcinoma in situ of the breast: a comparison between African-American and White-American women. Breast Cancer Res Treat 131(2):561–570. doi: 10.1007/s10549-011-1742-5 CrossRefPubMedCentralPubMedGoogle Scholar
- 41.Perkins P, Cooksley CD, Cox JD (1996) Breast cancer. Is ethnicity an independent prognostic factor for survival? Cancer 78(6):1241–1247. doi: 10.1002/(SICI)1097-0142(19960915)78:6<1241:AID-CNCR11>3.0.CO;2-0 CrossRefPubMedGoogle Scholar
- 49.Wirtz HS, Boudreau DM, Gralow JR, Barlow WE, Gray S, Bowles EJ, Buist DS (2014) Factors associated with long-term adherence to annual surveillance mammography among breast cancer survivors. Breast Cancer Res Treat 143(3):541–550. doi: 10.1007/s10549-013-2816-3 CrossRefPubMedCentralPubMedGoogle Scholar